Recently equities researchers at Janney Montgomery Scott initiated a coverage on NTRI and gave it a neutral rating. The company is stepping up its marketing efforts and has hired actress Melissa Joan Hart as its newest brand ambassador. Meanwhile, NTRI has retraced all of the recent move from $7.21 to $9.08. The fall has been pretty brisk, and it has lost more than 15% in last one month. It is technically very weak and is trading far below its short term averages (200 DMA of $8.78 and 50 DMA of $8.35. On a 52 week basis also, it is down nearly 30%. The way it has been falling, it seems that it will not be able to hold the supports that easily. The volumes have tapered down, with the 10 day average of 219K being less than the 3 month average of 298K. The financial results have not been supportive of any uptrend. The revenues and net income have been falling continuously. The company expects a change in the trend as it expects the general economic conditions to improve. However, the management expects a net loss in Q1'13. For the full year 2013, it expects a significant turnaround with an expected net profit of 23-33 cents per share compared with a net loss on 10 cents per share in 2012. In the same market, however, companies have been doing well. New product launches are happening and the company has to find ways to reverse the declines. ChromaDex Corporation (CDXC) has launched a low caffeine drink (Purenergy) recently and other companies have also been able to launch product ranges. This product also find uses in weight management due to the presence of CDXC's patented ingredient pterostilbene. NTRI should be on the lookout for new products which can add to the top line and be more profitable.